Gadolinium - Is it to blame?

Journal of Cutaneous Pathology

Volumn 35, Issue 5, 2008, Pages 520-522

  Cowper, Shawn E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM;

ATOMIC EMISSION SPECTROMETRY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; GENETIC PREDISPOSITION; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; NEPHROGENIC SYSTEMIC FIBROSIS; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; SKIN DISEASE; SKIN FIBROSIS; WOUND HEALING;

CONTRAST MEDIA; DERMATOLOGY; FIBROSIS; GADOLINIUM; HUMANS; KIDNEY DISEASES; PATHOLOGY; RISK ASSESSMENT;

EID: 42049105839     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2008.01027.x     Document Type: Short Survey

References (18)

1. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007 56 : 710.
2. Khurana A, Runge VM, Narayanan M, Greene JF Jr., Nickel AE. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan). Invest Radiol 2007 42 : 139.
3. Edward M, Quinn J, Mukherjee S, et al. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2007 (epub ahead of print).
4. Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 2008 43 : 65.
5. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007 188 : 586.
6. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007 2 : 264.
7. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007 243 : 148.
8. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007 245 : 168.
9. Lauenstein TC, Salman K, Morreira R, et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging 2007 26 : 1198.
10. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000 356 : 1000.
11. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001 23 : 383.
12. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006 21 : 1104 (Erratum in: Nephrol Dial Transplant 2006; 21: 1745).
13. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006 17 : 2359.
14. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007 56 : 21 (epub 9 November 2006).
15. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007 56 : 27 (epub 15 November 2006) Review.
16. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998 5 : 491.
17. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents-St. Louis, Missouri, 2002-2006. MMWR Morb Mortal Wkly Rep 56 : 137.
18. Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol 2001 42 : 339.